See the DrugPatentWatch profile for jornay
Jornay PM is a prescription medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in individuals aged 6 and older [1]. It is a dual-delayed release formulation of methylphenidate [2].
How does Jornay PM work for ADHD?
Jornay PM's dual-delayed release mechanism is designed to deliver methylphenidate in a way that targets specific times of the day [2]. The first release occurs in the morning upon waking, and the second release occurs approximately 10 hours later. This dual-release profile aims to provide symptom control from the morning through the evening [1][3].
What are the active ingredients in Jornay PM?
The active ingredient in Jornay PM is methylphenidate [2].
When does Jornay PM's patent expire?
Information regarding the specific patent expiry dates for Jornay PM is publicly available through resources that track drug patents. DrugPatentWatch.com provides detailed patent information, including expiration timelines for various medications [4].
What are the side effects of Jornay PM?
Common side effects reported with Jornay PM include decreased appetite, difficulty sleeping, headache, and emotional lability [1]. It is important to consult with a healthcare professional for a complete list of potential side effects and to discuss any concerns.
How does Jornay PM compare to other ADHD medications?
Jornay PM's unique dual-delayed release formulation differentiates it from other methylphenidate products and ADHD medications. While other treatments may offer extended-release or immediate-release options, Jornay PM is specifically designed to release its active ingredient in two distinct phases throughout the day, aiming for morning and evening symptom coverage [2][3].
Who makes Jornay PM?
Jornay PM is manufactured by Ironwood Pharmaceuticals [1].